ID   K562/GM-CSF
AC   CVCL_A8HT
SY   K562 GM-CSF; K562GM-CSF; GM-K562
DR   Wikidata; Q107115522
RX   PubMed=10466632;
RX   PubMed=23170257;
RX   PubMed=32289117;
CC   Population: Caucasian.
CC   Biotechnology: Used for the production of the Sorento Therapeutics STI-6991 SARS-CoV-2 (COVID-19) vaccine candidate. The cell line which is lethally irradiated is used to produce the recombinant SARS-CoV-2 spike protein rSARS-CoV-2 which is the active part of the vaccine formulation (PubMed=32289117).
CC   Characteristics: Does not express HLA class I or II antigens, potentially decreasing the magnitude of the alloresponses generated on repeated immunizations (PubMed=10466632).
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:2434; CSF2.
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) (HygR).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 20-05-21; Last updated: 19-12-24; Version: 9
//
RX   PubMed=32289117; DOI=10.1016/j.medidd.2020.100026; PMCID=PMC7144842;
RA   Ji, Henry
RA   Yan, Ying
RA   Ding, Bei-Bei
RA   Guo, Wen-Zhong
RA   Brunswick, Mark
RA   Niethammer, Andreas G.
RA   SooHoo, Williams
RA   Smith, Robin
RA   Nahama, Alexis
RA   Zhang, Yan-Liang
RT   "Novel decoy cellular vaccine strategy utilizing transgenic
RT   antigen-expressing cells as immune presenter and adjuvant in vaccine
RT   prototype against SARS-CoV-2 virus.";
RL   Med. Drug Discov. 5:100026.1-100026.2(2020).
//
RX   PubMed=23170257; DOI=10.4161/onci.20954; PMCID=PMC3494623;
RA   Brusic, Ana
RA   Hainz, Ursula
RA   Wadleigh, Martha
RA   Neuberg, Donna
RA   Su, Mei
RA   Canning, Christine M.
RA   DeAngelo, Daniel J.
RA   Stone, Richard M.
RA   Lee, Jeng-Shin
RA   Mulligan, Richard C.
RA   Ritz, Jerome
RA   Dranoff, Glenn
RA   Sasada, Tetsuro
RA   Wu, Catherine Ju-Ying
RT   "Detecting T-cell reactivity to whole cell vaccines: proof of concept
RT   analysis of T-cell response to K562 cell antigens in CML patients.";
RL   OncoImmunology 1:1095-1103(2012).
//
RX   PubMed=10466632; DOI=10.1089/10430349950017347;
RA   Borrello, Ivan
RA   Sotomayor, Eduardo M.
RA   Cooke, Sara
RA   Levitsky, Hyam I.
RT   "A universal granulocyte-macrophage colony-stimulating
RT   factor-producing bystander cell line for use in the formulation of
RT   autologous tumor cell-based vaccines.";
RL   Hum. Gene Ther. 10:1983-1991(1999).
//